Hervé Tilly
#133,821
Most Influential Person Now
Researcher
Hervé Tilly's AcademicInfluence.com Rankings
Hervé Tillycomputer-science Degrees
Computer Science
#6038
World Rank
#6367
Historical Rank
Computational Linguistics
#963
World Rank
#977
Historical Rank
Machine Learning
#1824
World Rank
#1848
Historical Rank
Artificial Intelligence
#2075
World Rank
#2110
Historical Rank
Hervé Tillymathematics Degrees
Mathematics
#6376
World Rank
#8841
Historical Rank
Measure Theory
#1301
World Rank
#1643
Historical Rank
Download Badge
Computer Science Mathematics
Hervé Tilly's Degrees
- PhD Computer Science Université Paris Cité
- Masters Computer Science Université Paris Cité
- Bachelors Mathematics Université Paris Cité
Similar Degrees You Can Earn
Why Is Hervé Tilly Influential?
(Suggest an Edit or Addition)Hervé Tilly's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. (2002) (2551)
- Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. (2005) (1312)
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. (2010) (1116)
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial (2011) (964)
- Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. (1998) (931)
- TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. (2011) (828)
- Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (636)
- Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). (2003) (538)
- Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. (1997) (524)
- Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). (1998) (503)
- LAZ3, a novel zinc–finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas (1993) (457)
- Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. (2000) (453)
- Treatment of older patients with mantle-cell lymphoma. (2012) (453)
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (2019) (394)
- Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. (2011) (384)
- An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. (2011) (383)
- Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients (2003) (377)
- Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. (2003) (343)
- Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. (2011) (330)
- ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. (2005) (324)
- LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. (1994) (322)
- CD30‐positive large cell lymphomas (‘Ki‐1 lymphoma’) are associated with a chromosomal translocation involving 5q35 (1990) (321)
- A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. (1995) (316)
- Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial (2011) (314)
- Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. (1997) (304)
- LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. (1989) (270)
- Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. (2014) (269)
- Prognostic value of chromosomal abnormalities in follicular lymphoma. (1994) (269)
- Rituximab after Autologous Stem‐Cell Transplantation in Mantle‐Cell Lymphoma (2017) (261)
- Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. (1990) (256)
- Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. (2013) (256)
- Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. (2004) (246)
- Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). (2006) (245)
- Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. (2008) (239)
- Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. (1991) (239)
- An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax (2013) (231)
- CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. (2013) (229)
- CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. (2007) (228)
- All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. (1992) (224)
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma (2018) (222)
- Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. (2015) (221)
- Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. (1997) (220)
- Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. (1994) (207)
- Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. (2016) (207)
- Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. (2003) (204)
- Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. (2002) (203)
- Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. (2003) (200)
- MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. (2015) (197)
- Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. (2020) (192)
- Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. (2012) (191)
- Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients (2000) (189)
- Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. (1997) (187)
- Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma (2014) (181)
- Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). (1993) (180)
- Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. (2012) (175)
- Does treatment with ARA-C in low dosage cause differentiation of leukemic cells? (1983) (174)
- Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study (2016) (174)
- Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. (2011) (171)
- Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. (1993) (168)
- 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. (2013) (168)
- Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. (2012) (156)
- Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle. (1999) (155)
- Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. (2013) (153)
- Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. (2012) (153)
- Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation. (2008) (150)
- Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. (2006) (150)
- Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). (2019) (149)
- Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM) (2000) (148)
- Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. (1996) (146)
- Translocations involving band 3q27 and Ig gene regions in non-Hodgkin's lymphoma. (1992) (144)
- TTF, a gene encoding a novel small G protein, fuses to the lymphoma-associated LAZ3 gene by t(3;4) chromosomal translocation. (1995) (143)
- Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. (2014) (142)
- Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. (2003) (142)
- Genome-wide association study identifies multiple susceptibility loci for diffuse large B-cell lymphoma (2014) (140)
- Pyothorax-Associated Lymphoma: A Peculiar Clinicopathologic Entity Derived From B Cells at Late Stage of Differentiation and With Occasional Aberrant Dual B- and T-Cell Phenotype (2002) (140)
- Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. (2008) (139)
- Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma (2015) (138)
- Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas (2007) (137)
- Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. (2016) (136)
- Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. (2017) (135)
- Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study (2007) (134)
- Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial (2016) (132)
- Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study (2019) (131)
- Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent TFH–B cell axis (2009) (129)
- Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. (2010) (127)
- Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. (2009) (122)
- Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy (2014) (121)
- Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the Groupe d'Etude des Lymphomes Agressifs. (1991) (118)
- Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial (2013) (117)
- Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study (2013) (111)
- Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. (2017) (110)
- Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. (1992) (109)
- Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. (2013) (107)
- A gene-expression profiling score for outcome prediction disease in patients with follicular lymphoma: a retrospective analysis on three international cohorts (2018) (107)
- Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. (2021) (105)
- Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. (2001) (103)
- Impact of the use of autologous stem cell transplantation at first relapse both in naïve and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study (2011) (100)
- High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis (2012) (100)
- Cytogenetic studies in untreated Hodgkin's disease. (1991) (99)
- International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a comparison of IPI, R-IPI and NCCN-IPI. (2020) (98)
- The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab (2008) (98)
- Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. (1997) (96)
- Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. (2015) (95)
- Rituximab ( Anti-CD 20 Monoclonal Antibody ) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma : A Multicenter Phase II Study (1998) (95)
- Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. (2019) (94)
- A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. (2008) (93)
- Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study (2015) (93)
- A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (2013) (93)
- Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma (2016) (92)
- High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. (2000) (91)
- The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age (2011) (91)
- Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B‐cell lymphoma treated with immunochemotherapy (2014) (91)
- Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. (2004) (90)
- Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte. (1999) (88)
- Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). (2007) (88)
- Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia. (2009) (88)
- Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing. (2017) (88)
- Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). (2016) (86)
- Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B‐cell lymphoma (2016) (83)
- The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis. (2007) (83)
- TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm (2011) (83)
- Autologous stem cell transplantation in elderly patients (≥60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry (2008) (83)
- Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (83)
- Chromosome abnormalities in peripheral T-cell lymphoma. (2000) (82)
- Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA (2011) (81)
- Targetable activating mutations are very frequent in GCB and ABC diffuse large B‐cell lymphoma (2014) (80)
- Follicular lymphoma without t(14;18) and with BCL-6 rearrangement: a lymphoma subtype with distinct pathological, molecular and clinical characteristics (2002) (80)
- Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients. (1994) (80)
- FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. (2017) (78)
- Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia (1993) (78)
- Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B‐cell lymphoma (2016) (77)
- Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. (2019) (77)
- Granulocyte–macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial) (1999) (76)
- Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA (2012) (75)
- Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. (2000) (75)
- Phase II trial of zanolimumab (HuMax‐CD4) in relapsed or refractory non‐cutaneous peripheral T cell lymphoma (2010) (75)
- Cloning of a breakpoint cluster region at band 3q27 involved in human non‐Hodgkin's lymphoma (1993) (74)
- Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. (2018) (74)
- Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly (2015) (72)
- Low‐dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients (1985) (72)
- Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte. (2000) (69)
- Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases (2016) (68)
- Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma (2017) (68)
- The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma (2011) (68)
- Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. (2017) (67)
- Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte. (2010) (67)
- R-CHOP14 Compared to R-CHOP21 in Elderly Patients with Diffuse Large B-Cell Lymphoma: Results of the Interim Analysis of the LNH03-6B GELA Study (2009) (67)
- Multicenter Outbreak of Infections by Saprochaete clavata, an Unrecognized Opportunistic Fungal Pathogen (2014) (67)
- Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis (2015) (67)
- Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. (2009) (66)
- Characterisation of BCL2-JH rearrangements in follicular lymphoma: PCR detection of 3′ BCL2 breakpoints and evidence of a new cluster (2000) (66)
- Hepatosplenic gamma/delta T-cell lymphoma: a report of two cases in immunocompromised patients, associated with isochromosome 7q. (1997) (66)
- Interleukin-2 treatment in lymphoma: a phase II multicenter study. (1994) (66)
- Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay: A CALYM Study. (2015) (65)
- Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. (1997) (65)
- Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma (2016) (64)
- Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia (1997) (61)
- Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. (2012) (61)
- Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (61)
- Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes (2000) (61)
- Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma (2018) (60)
- The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT (2013) (59)
- A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia. (1991) (59)
- Distribution of BCL2 breakpoints in follicular lymphoma and correlation with clinical features: specific subtypes or same disease? (2002) (59)
- INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS (2017) (59)
- Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. (1993) (58)
- A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts (2018) (58)
- High total metabolic tumor volume at baseline predicts survival independent of response to therapy (2020) (57)
- Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort (2018) (56)
- Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. (2014) (56)
- S(mu) mutation patterns suggest different progression pathways in follicular lymphoma: early direct or late from FL progenitor cells. (2008) (55)
- Ketoconazole-induced fulminant hepatitis. (1985) (55)
- Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients (2007) (54)
- Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). (2018) (54)
- Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma (2017) (54)
- (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. (2011) (54)
- Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease (2009) (53)
- Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index (2014) (53)
- De novo acute B cell leukemia/lymphoma with t(14;18) (2000) (51)
- Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). (2010) (51)
- Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. (2019) (51)
- Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). (2012) (50)
- Hematopoietic reconstitution after autologous blood stem cell transplantation: A report of 46 cases (1987) (50)
- Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years. (2006) (48)
- STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model (2013) (48)
- Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. (2018) (48)
- Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients (2017) (47)
- Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma (2012) (46)
- Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials (2018) (46)
- Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years (2017) (46)
- A Phase I/II Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Malignant Disease (2008) (45)
- Treatment of leukemia with low dose Ara-C: a study of 159 cases. (1985) (45)
- Concurrent activation of MYC and BCL2 in B cell non-Hodgkin lymphoma cell lines by translocation of both oncogenes to the same immunoglobulin heavy chain locus. (1996) (45)
- A phase II, single‐arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B‐cell lymphoma (2016) (45)
- Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. (2012) (44)
- Treatment of leukemia with low-dose ara-C: a study of 160 cases. (1985) (43)
- Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. (1999) (43)
- HAEMOPOIETIC RECONSTITUTION AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN ACUTE LEUKAEMIA (1986) (43)
- Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group (2016) (42)
- Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. (2016) (42)
- A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features (2020) (41)
- Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (2009) (41)
- Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS. (1999) (41)
- Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma (2013) (40)
- Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma (2015) (39)
- Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma (2016) (39)
- Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. (2019) (39)
- Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (2014) (38)
- High total metabolic tumor volume at baseline allows discrimination of survival even in patients aged 60 to 80 years responding to R-CHOP. (2020) (38)
- Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma (2013) (38)
- Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). (2006) (38)
- Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy? (2015) (38)
- Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old. (2005) (38)
- Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study (2019) (37)
- Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study (2014) (37)
- Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte. (1994) (37)
- Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia. (1993) (35)
- Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier: A CALYM Study. (2017) (35)
- Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. (2018) (34)
- The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B‐cell lymphoma (2013) (34)
- Phase I Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma (NHL). (2009) (34)
- Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA. (2020) (33)
- Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas (2008) (32)
- Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age (1997) (31)
- R-CHOP Versus R-FC Followed by Maintenance with Rituximab Versus Interferon-Alfa: Outcome of the First Randomized Trial for Elderly Patients with Mantle Cell Lymphoma (2011) (31)
- Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio (2019) (31)
- Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC (2016) (30)
- Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma? (2007) (30)
- Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era (2015) (30)
- Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value (2009) (29)
- Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Groupe d'Etudes des Lymphomes de l'Adulte. (1996) (29)
- Comparison of a quantitative PCR method with FISH for the assessment of the four aneuploidies commonly evaluated in CLL patients (2007) (29)
- Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma. (2008) (29)
- Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. (1996) (29)
- Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). (2013) (29)
- Residual disease in B-cell chronic lymphocytic leukemia patients and prognostic value. (1994) (29)
- Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia (1997) (29)
- Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients (2016) (29)
- Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B‐cell non‐Hodgkin lymphoma: Relationship with tumor aggressiveness (2005) (29)
- ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients (2019) (28)
- Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma (2019) (28)
- Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia (2005) (28)
- Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (28)
- RCHOP and RDHAP Followed by Autologous Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL) : Final Results of a Phase II Study from the GELA (2008) (28)
- Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). (2011) (27)
- No Role for Chemoradiotherapy When Compared with Chemotherapy Alone in Elderly Patients with Localized Low Risk Aggressive Lymphoma: Final Results of the LNH93-4 GELA Study. (2005) (27)
- Intense paraneoplastic neutrophilic leukemoid reaction related to a G‐CSF‐Secreting lung sarcoma (2005) (27)
- Performance of Serum Biomarkers for the Early Detection of Invasive Aspergillosis in Febrile, Neutropenic Patients: A Multi-State Model (2013) (27)
- Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte. (1996) (27)
- Primary cutaneous medium and large cell lymphomas other than mycosis fungoides. An immunohistological and follow‐up study on 54 cases (1995) (27)
- PreB1 (CD10-) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des Leucémies. (1998) (26)
- PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma (2015) (26)
- A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05-1T trial. (2016) (26)
- Timed sequential chemotherapy for advanced acute myeloid leukemia. (1996) (26)
- Zanolimumab (HuMax-CD4™), a Fully Human Monoclonal Antibody: Efficacy and Safety in Patients with Relapsed or Treatment-Refractory Non-Cutaneous CD4+ T-Cell Lymphoma. (2007) (26)
- Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia (2016) (26)
- Lactobacillus species as emerging pathogens in neutropenic patients (1997) (26)
- Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. (2015) (25)
- Neurological toxicity related to pefloxacin. (1988) (25)
- Significant Correlation between Survival Endpoints and Exposure to Ofatumumab (HuMax-CD20) in Chronic Lymphocytic Leukemia. (2006) (25)
- Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease (2009) (25)
- Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non‐Hodgkin's lymphoma (1996) (24)
- HIV-associated non-Hodgkin's lymphomas: clinical characteristics and outcome. The experience of the French Registry of HIV-associated tumors. (1991) (24)
- Hepatic veno-occlusive disease following bone marrow transplantation treated by prostaglandin E1. (1991) (24)
- Superiority of late over early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma: A randomized study from the GELA: LNH RP 93 (1997) (24)
- Invasive Geotrichum clavatum Fungal Infection in an Acute Myeloid Leukaemia Patient: A Case Report and Review (2014) (24)
- Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles (2019) (24)
- The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party. (2014) (23)
- Is There Still a Place for Total Body Irradiation (TBI) In the Conditioning Regimen of Autologous Stem Cell Transplantation In Mantle Cell Lymphoma ?: a Retrospective Study From the Lymphoma Working Party of the EBMT (2010) (23)
- Autologous hematopoietic stem cell transplantation in intermediate and high grade non-Hodgkin's lymphoma: a review. (1993) (23)
- HuMax CD20 Fully Human Monoclonal Antibody in Chronic Lymphocytic Leuchemia. Early Results from an Ongoing Phase I/II Clinical Trial. (2005) (23)
- Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6B study. (2011) (23)
- PVRL2 is translocated to the TRA@ locus in t(14;19)(q11;q13)‐positive peripheral T‐cell lymphomas (2007) (23)
- Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. (2021) (23)
- Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia (1996) (22)
- Change in energy and protein status during chemotherapy in patients with acute leukemia (1988) (22)
- Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). (2014) (22)
- Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – Updated Results with Encouraging Progression Free Survival (PFS) Data From a Phase II Study In Patients with Relapsed/Refractory Indolent NHL (iNHL) (2010) (22)
- A multivariate analysis of the survival of patients with aggressive lymphoma (1998) (22)
- Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes (2012) (22)
- Low-dose cytarabine: persistence of a clonal abnormality during complete remission of acute nonlymphocytic leukemia. (1986) (22)
- CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): A pilot study from the GELA. (2004) (22)
- Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level. (2015) (22)
- 90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients (2010) (22)
- An uncommon association: Sjögren's syndrome and autoimmune myelofibrosis. (1999) (21)
- Somatic mutations of cell-free circulating DNA detected by targeted next-generation sequencing and digital droplet PCR in classical Hodgkin lymphoma (2018) (21)
- Molecular cloning of a t(11; 14)(q13;q32) translocation breakpoint centromeric to the BCLI‐MTC (1994) (21)
- Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series (2011) (21)
- An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. (2018) (21)
- Hematological toxicity of ticlopidine (1994) (21)
- A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte. (1998) (21)
- Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial. (2012) (20)
- BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial (2017) (19)
- Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. (2018) (19)
- Reproducibility of Baseline Tumour Metabolic Volume Measurements in Diffuse Large B-Cell Lymphoma: Is There a Superior Method? (2021) (19)
- Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma (2017) (19)
- Follicle center lymphoma is associated with significantly elevated levels of BCL-6 expression among lymphoma subtypes, independent of chromosome 3q27 rearrangements (2002) (19)
- A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results. (1993) (19)
- High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma. (1998) (19)
- Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma (2007) (19)
- Effect of chemotherapy on resting energy expenditure in patients with non‐Hodgkin's lymphoma results of a sequential study (1990) (19)
- First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa (2016) (18)
- Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma (2018) (18)
- Clinical and biological relevance of single-nucleotide polymorphisms and acquired somatic mutations of the BCL6 first intron in follicular lymphoma (2005) (18)
- Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) (2013) (18)
- Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). (2013) (18)
- Human monocytes synthesize hyaluronidase (2002) (18)
- The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential (2017) (18)
- A Phase Ib Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL): The Ro-CHOP Study (2012) (17)
- 10 Years Follow-up of the GELA LNH98.5 Study, First Randomized Study Comparing R-CHOP to CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma. (2009) (17)
- Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update (2004) (17)
- Defining signatures of peripheral T-cell lymphoma with a targeted 20-marker gene expression profiling assay (2019) (17)
- In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas (2016) (17)
- Two patterns of chromosomal breakpoint locations on the immunoglobulin heavy-chain locus in B-cell lymphomas with t(3;14)(q27;q32): relevance to histology (2006) (17)
- A Phase Ib Study of Obinutuzumab Combined with Lenalidomide for Relapsed/Refractory Follicular B-Cell Lymphoma (2014) (16)
- Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. French Society of Bone Marrow Transplantation. (1997) (16)
- INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (2019) (16)
- Early 18fluorodeoxyglucose PET Scan as a Prognostic Tool in Diffuse Large B-Cell Lymphoma Patients Treated with An Anthracycline-Based Chemotherapy Plus Rituximab. (2009) (16)
- Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) (2018) (16)
- Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study. (2012) (16)
- A Prospective Randomized Study Comparing Dose Intensive Immunochemotherapy with R-ACVBP vs Standard R-CHOP In Younger Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-2B (2010) (16)
- Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies (2016) (16)
- Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years. (2004) (16)
- Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial (2017) (16)
- RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma. (2018) (15)
- The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma. (2021) (15)
- Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review (2019) (15)
- Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era (2015) (15)
- Long term results of the GELA study, R-CHOP vs. CHOP in elderly patients with diffuse large B-cell lymphoma. (2004) (15)
- Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay (2017) (15)
- Long‐term fatigue in survivors of non‐Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross‐sectional study (2019) (15)
- Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma (2016) (15)
- Intravascular large B-Cell lymphoma with bone marrow involvement and superior sagittal sinus thrombosis: report of a case successfully treated with a CHOP/rituximab combination regimen. (2005) (15)
- Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999) (2011) (15)
- Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study. (2017) (15)
- Prognostic Factors and Long Term Outcome of 138 Adults with Systemic Anaplastic Large-Cell Lymphoma: a Retrospective Study by the Groupe d'Etude Des Lymphomes De l'Adulte (GELA) (2010) (15)
- CHROMOSOMAL ABNORMALITIES IN SECONDARY EWING'S SARCOMA (1984) (15)
- SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL). (2006) (15)
- Diffuse large B-cell lymphoma and Burkitt lymphoma in adults and children. In: The European Hematology Association roadmap for European hematology research: a consensus document (2016) (14)
- Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study (2018) (14)
- Treatment of follicular lymphoma: current status (2008) (14)
- Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant (2011) (14)
- Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab‐naive, recurrent/refractory follicular non‐Hodgkin lymphoma with high tumor burden (2010) (14)
- HACE1 is a putative tumor suppressor gene in B-cell lymphomagenesis and is down-regulated by both deletion and epigenetic alterations. (2016) (14)
- ¹⁸F-FDG-PET/CT Imaging in Patients with Febrile Neutropenia and Haematological Malignancies. (2015) (14)
- Spontaneous remission in three cases of AML M5 with NPM1 mutation (2015) (13)
- Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study (2016) (13)
- Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma. (2014) (13)
- Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. (2020) (13)
- Rituximab vs Observation after High-Dose Consolidative First-Line Chemotherapy (HDC) with Autologous Stem Cell Transplantation in Poor Risk Diffuse Large B-Cell Lymphoma. Final Analysis of the LNH98-B3 GELA Study. (2005) (13)
- POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL. (2019) (13)
- Final Results of a Randomized Phase 2 Multicenter Study of Two Bortezomib Schedules In Patients with Recurrent or Refractory Follicular Lymphoma. Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study FL-05 (2010) (13)
- 90Yttrium ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory. follicular lymphoma. GELA phase II study (2007) (13)
- Hodgkin’s Disease Staging by FDG PET/CT in a Pregnant Woman (2014) (13)
- Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. (2007) (12)
- Survival Impact of Rituximab Combined to ACVBP (R-ACVBP) in 209 Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Upfront High-Dose Consolidative Autotransplantation (HDC) : A GELA Phase II Study (2008) (12)
- Does enhanced CT influence the biological GTV measurement on FDG-PET images? (2013) (12)
- Del(14)(q22) in diffuse B-cell lymphocytic lymphoma. (1988) (12)
- Immunological evaluation of harvested stem cells obtained by leukapheresis after chemotherapy (1992) (12)
- Voltage-Gated Potassium Channel Antibody Paraneoplastic Limbic Encephalitis Associated with Acute Myeloid Leukemia (2013) (12)
- [Auto-immune manifestations in Non-Hodgkin's lymphoma]. (2005) (12)
- FCGR3A/2A polymorphisms and diffuse large B‐cell lymphoma outcome treated with immunochemotherapy: a meta‐analysis on 1134 patients from two prospective cohorts (2017) (12)
- Molecular Profile and FDG-PET Metabolic Volume at Staging in DLBCL—Response (2016) (12)
- Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma (2015) (12)
- Lenalidomide in combination with R-CHOP (R2-CHOP) in patients with high burden follicular lymphoma: phase 2 study. (2013) (12)
- Conventional cytogenetics of nodular lymphocyte-predominant Hodgkin's lymphoma (2007) (12)
- Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA. (2016) (11)
- Mutation mismatch repair gene deletions in diffuse large B-cell lymphoma (2013) (11)
- Phase II Study Of Anti-CD19 Antibody Drug Conjugate (SAR3419) In Combination With Rituximab: Clinical Activity and Safety In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT01470456) (2013) (11)
- Central nervous system relapse in patients over 80 years with diffuse large B‐cell lymphoma: an analysis of two LYSA studies (2018) (11)
- Epidemiology, pathology and treatment of non-follicular indolent lymphomas (2008) (11)
- Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study (2019) (11)
- Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study (2019) (11)
- Final Analysis of the RO-CHOP Phase Ib/II Study: Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL) (2014) (11)
- Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma (2020) (11)
- Bendamustine and rituximab in elderly patients with low‐tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study (2018) (10)
- Oncogenic events rather than antigen selection pressure may be the main driving forces for relapse in diffuse large B‐cell lymphomas (2017) (10)
- Somatic Mutations Detected in Plasma Cell-Free DNA By Targeted Sequencing: Assessment of Liquid Biopsy in Primary Central Nervous System Lymphoma (2015) (10)
- Rearrangements of immunoglobulin light and heavy chain genes and correlation with phenotypic markers in B-cell chronic lymphocytic leukemia. (1991) (10)
- Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma (2021) (10)
- SAR245409 Monotherapy in relapsed/refractory follicular lymphoma: preliminary results from the phase II ARD12130 study (2013) (10)
- Intensifi ed chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diff use large B-cell lymphoma ( LNH 032 B ) : an open-label randomised phase 3 trial (2011) (10)
- Invasive Aspergillosis in Neutropenic Patients During Hospital Renovation: Effectiveness of Mechanical Preventive Measures in a Prospective Cohort of 438 Patients (2015) (10)
- Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation (2021) (10)
- Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party (2020) (9)
- Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin’s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC) (2016) (9)
- Salmonella infection in hairy cell leukemia: Report of a case (1985) (9)
- Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated follicular lymphoma in need of systemic therapy. (2021) (9)
- Final results of the efficacy and safety of rasburicase (recombinant urate oxydase) for the prevention and treatment of hyperuricemia in patients with aggressive lymphoma (GRAAL 1 study). (2002) (9)
- Molecular characterization of 9p21 deletions shows a minimal common deleted region removing CDKN2A exon 1 and CDKN2B exon 2 in diffuse large b‐cell lymphomas (2011) (9)
- Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. (2012) (9)
- Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma. (2016) (9)
- Intronic BCL-6 mutations are preferentially targeted to the translocated allele in t(3;14)(q27;q32) non-Hodgkin B-cell lymphoma. (2003) (9)
- Daily evaluation of circulating granulocyte-monocyte progenitors during bone marrow recovery from induction therapy in acute leukemia. (1986) (9)
- Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study (2016) (9)
- Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. (2008) (9)
- Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma (2017) (9)
- Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy. (2010) (9)
- Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas (2011) (8)
- CD2+ CD19+ acute lymphoblastic leukaemia in 16 children and adults: clinical and biological features. The Groupe d'Etude Immunologique des Leucémies (G.E.I.L.) (1993) (8)
- [Intramedullary spinal cord metastasis and leptomeningeal involvement in Hodgkin's disease. Case report and review of the literature]. (1999) (8)
- Value of autologous bone marrow transplantation (ABMT) in 42 patients with follicular lymphomas responsive to conventional chemotherapy: a "France Autogreffe" study. (1996) (8)
- High Response Rate After 4 Courses of R-DHAP In Untreated Mantle Cell Lymphoma (MCL) Patients In the Ongoing Phase III Randomized GOELAMS and GELA LyMa Trial (2010) (8)
- Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group. (2020) (8)
- Result of FDG PET-CT Imaging After Immunochemotherapy Induction Is a Powerful and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: An Analysis From the PRIMA Study (2010) (8)
- EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: Recommendations for the Second Phase of the COVID-19 Pandemic (2021) (8)
- Obinutuzumab Versus Rituximab in Combination with ACVBP-14 or CHOP-14 Following a PET-Driven Strategy in Aa-IPI 1-3 DLBCL Patients (< 60 years): Third Planned Interim and Final Analyses of the Gained Trial (2017) (8)
- Cyberlindnera jadinii (teleomorph Candida utilis) candidaemia in a patient with aplastic anaemia: a case report (2018) (8)
- Safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-Cell lymphoma (DLBCL) treated with R-CHOP 14 or RCHOP21: Preliminary results of the LNH03-6B randomized GELA study. (2006) (8)
- Expression of the hyaluronan-binding glycoprotein hyaluronectin in leukemias. (1993) (8)
- Novel Ig V gene features of t(14;18) and t(3;14) de novo diffuse large B-cell lymphoma displaying germinal center-B cell like and non-germinal center-B cell like markers (2006) (8)
- Rituximab compared to observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor-risk diffuse large B-cell lymphoma: Updated results of the LNH98-B3 GELA study (2007) (8)
- Lenalidomide in Combination with CHOP in Patients with Angioimmunoblastic T-Cell Lymphoma (AITL): Final Analysis of Clinical and Molecular Data of a Phase 2 Lysa Study (2018) (8)
- Concomitant eosinophilia, fasciitis, and mycosis fungoides-like reaction with antinuclear autoantibodies in chronic myeloid leukaemia: role of a T-cell clone induced by imatinib. (2005) (8)
- Accurate Classification Of GCB/ABC and MYC/BCL2 Diffuse Large B-Cell Lymphoma With a 14 Genes Expression Signature and a Simple and Robust RT-MLPA Assay (2013) (8)
- Secondary Philadelphia chromosome in a patient with acute lymphoblastic leukemia. (2004) (8)
- R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): Final analysis of the LNH03-6B GELA study. (2012) (7)
- Germinal Center Phenotype Determined by Immunohistochemistry on Tissue Microarray Does Not Correlate with Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy in the Randomized Trial LNH98-5. A GELA Study. (2007) (7)
- Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party (2017) (7)
- R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2B (2011) (7)
- Low Suvmax Measured on Baseline FDG-PET/CT and Elevated β2 Microglobulin Are Negative Predictors of Outcome in High Tumor Burden Follicular Lymphoma Treated By Immunochemotherapy: A Pooled Analysis of Three Prospective Studies (2016) (7)
- Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA) (2015) (7)
- Eosinophilic leukemia associated with t(2;5)(p23;q31). (2002) (7)
- Characterization of three t(3;8)(q27;q24) translocations from diffuse large B-cell lymphomas (2008) (7)
- Sub-Cutaneous Rituximab-Minichop Versus Sub-Cutaneous Rituximab-Minichop + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More (SENIOR Study). a Multicentric Randomized Phase III Study of the Lysa (2019) (7)
- Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). (2012) (7)
- Prognostic value of pretherapy metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with diffuse large B-cell lymphoma (DLBCL) (2012) (7)
- Efficacy and Safety of Prophylactic Use of Darbepoetin Alfa in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results of the Interim Analysis of the LNH03-6B GELA Study. (2009) (7)
- Phase I/II study of SPC2996, an RNA antagonist of Bcl-2, in patients with advanced chronic lymphocytic leukemia (CLL) (2007) (7)
- Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (2017) (7)
- Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study (2015) (7)
- R-DHA-Oxaliplatin before Autologous Stem Cell Transplantation Prolongs PFS and OS As Compared to R-DHA-Carboplatin and R-DHA-Cisplatin in Patients with Mantle Cell Lymphoma, a Subgroup Analysis of the LyMa Trial (2017) (7)
- Optical neuropathy possibly related to arsenic during acute promyelocytic leukemia treatment (2008) (6)
- [Treatment of acute myeloblastic leukemia in elderly patients with low-dose cytosine arabinoside]. (1985) (6)
- Early Results of a Phase Ib/II Dose-Escalation Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphomas (PTCL) (2011) (6)
- Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory b-cell non-Hodgkin’s lymphoma (NCT00796731). (2012) (6)
- Cyclosporin for treatment of life‐threatening alloimmunization (1990) (6)
- Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma (2021) (6)
- Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas. (2022) (6)
- Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study (2010) (6)
- REAL‐WORLD RESULTS ON CD19 CAR T‐CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE PROGRAM (2019) (6)
- Influence of PET/CT on radiologists and contrast-enhanced CT on nuclear medicine physicians in patients with lymphoma. (2011) (6)
- Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA. (2020) (6)
- A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph-positive chronic myelogenous leukaemia: interferon alfa-2b and hydroxyurea with or without cytosine arabinoside , preliminary results. (1991) (6)
- Discovery of Candidate Predictors of Response to Tazemetostat in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Using NGS Technology on ctDNA Samples Collected Pre-Treatment (2017) (6)
- Correlations between baseline 18F-FDG PET tumour parameters and circulating DNA in diffuse large B cell lymphoma and Hodgkin lymphoma (2020) (6)
- A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B‐CELL LYMPHOMA (2017) (5)
- Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study. (2012) (5)
- Peripheral blood stem cells collected before and after leukapheresis in the very early remission phase of hematopoietic malignancies (1989) (5)
- Autoimmune phenomena associated with cutaneous aseptic necrosis during interferon-alpha treatment for chronic myelogenous leukaemia. (1995) (5)
- The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (2021) (5)
- Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT (2020) (5)
- Lymphomes non hodgkiniens (2006) (5)
- MYC Gene Simple Hit Is a Strong Independent Predictive Factor of Survival in Diffuse Large B-Cell Lymphomas in Contrast to MYC Double-Hit Gene Alterations: A Study by the Groupe d'Etude Des Lymphomes De l'Adulte (2012) (5)
- Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma. (2020) (5)
- Prognostic impact of diagnosis to treatment interval (DTI) in diffuse large B-cell lymphoma patients: a real-life monocentric study (2018) (5)
- A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell Lymphoma (2016) (5)
- A phase I study of escalating doses of lenalidomide combined with R-CHOP (R2-CHOP) for front-line treatment of B-cell lymphomas. (2010) (5)
- Transformation of an Unclassified Myeloproliferative Neoplasm with a Rare BCR-JAK2 Fusion Transcript Resulting from the Translocation (9;22)(p24;q11) (2015) (5)
- Recurrent disruption of the Iμ splice donor site in t(14;18) positive lymphomas : A potential molecular basis for aberrant downstream class switch recombination (2007) (5)
- Chromosomal abnormalities in two cases of plasma cell leukemia. (1991) (5)
- Outcomes after first-line immunochemotherapy for primary mediastinal B cell lymphoma patients: a LYSA study. (2021) (5)
- Rituximab and Reduced Dose CHOP (R-mini-CHOP) for Patients Over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-7B (2010) (5)
- A phase I study of IV aflibercept (Afl) in combination with R-CHOP in untreated patients (pts) with B-cell lymphoma. (2010) (5)
- Prognostic factors of acute non lymphoblastic leukemia in children and adults. Results from two multicentric trials (705 patients). (1990) (5)
- Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant (2010) (5)
- Pre-Phase Chemotherapy Followed By Ofatumumab (OFA) and Reduced Dose CHOP (OFA-mini-CHOP) for Patients over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – a Lymphoma Study Association (LYSA) Prospective Phase II Study (LNH09-7B) (2014) (5)
- Reduced Intensity Allogeneic Stem Cell Transplantation for Follicular Lymphoma Results in An Improved Progression Free Survival When Compared to Autologous Stem Cell Transplantation. An Analysis from the Lymphoma Working Party of the EBMT (2008) (5)
- Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL). (2014) (4)
- Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study (2018) (4)
- Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma (NHL) with the ACVBP regimen. A GELA (Groupe d'Etude des Lymphomes de l'Adulte) cohort study on 2849 patients. (2001) (4)
- Human herpesvirus-6 acute limbic encephalitis after unrelated umbilical cord blood transplantation successfully treated with ganciclovir (2015) (4)
- A Multicentric Prospective Phase 2 Study of Intravenous Rituximab and Intrathecal Liposomal Cytarabine in Combination with C5R Protocol Followed by Brain Radiotherapy for Immunocompetent Patients with Primary CNS Lymphoma: A Lymphoma Study Association (LYSA) Trial (2012) (4)
- Autologous stem cell transplantation (ASCT) as consolidation therapy for patients with low-intermediate (LI) risk diffuse large B-cell lymphoma (DLBCL) and overexpression of bcl2 protein. Results of the first interim analysis of the GELA trial LNH98-B2. (2004) (4)
- Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The French Lymphoma Study Association (LYSA) registry data. (2018) (4)
- Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years (2021) (4)
- Impact of rituximab on stem cell mobilization following ACVBP regimen in poor‐risk patients with diffuse large B‐cell lymphoma: results from a large cohort of patients (2013) (4)
- A recurrent clonally distinct Burkitt lymphoma case highlights genetic key events contributing to oncogenesis (2019) (4)
- IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT) (2017) (4)
- 90yttrium Ibritumomab Tiuxetan (zevalin) Combined With Beam (z-beam) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed Or Refractory Follicular Lymphoma. a Gela Phase Ii Prospective Study (2009) (4)
- Characteristics of Refractory and Relapsing Patients with Diffuse Large B-Cell Lymphoma. (2008) (4)
- Sternum tumour revealing a chronic myeloid leukaemia. (1998) (4)
- Rituximab Combined to ACVBP (R-ACVBP) as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Preliminary Results on 119 Patients of a GELA Phase II Study. (2006) (4)
- Defining the signatures of peripheral T-cell lymphoma, with a targeted 20-markers gene expression profiling assay (RT-MLPA) (2019) (4)
- Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas (2021) (4)
- Long Term Follow-up of the GELF86 French and Belgian Trials : Complete Remission after First Line Treatment with Conventional Chemotherapy in Newly Diagnosed Follicular Lymphoma Patients Correlates with Prolonged Overall Survival Compared with Partial Remission. (2008) (4)
- HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R‐CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY (2019) (4)
- IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era (2013) (4)
- Alternance of chemotherapy does not improve results in aggressive non-Hodgkin's lymphoma: A prospective randomized study on 884 patients LNH87 protocol group 3: A gela study (1996) (4)
- Unusual complex hyperdiploid karyotypes in myelodysplastic syndromes. (2006) (4)
- Effect of Rituximab and/or High-Dose Therapy with Autotransplant at Time of Relapse in Patients with Follicular Lymphoma. (2007) (4)
- [Splenectomy in chronic idiopathic thrombopenic purpura in adults. Apropos of 49 cases]. (1989) (4)
- Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC) (2019) (4)
- [Acute respiratory distress syndrome due to pneumonitis following intrathecal methotrexate administration]. (2003) (4)
- Rituximab maintenance therapy for follicular lymphoma – Authors' reply (2011) (4)
- Circulating tumor DNA: an important tool in precision medicine for lymphoma (2018) (4)
- Correction to: Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma (2018) (4)
- Improving high-resolution copy number variation analysis from next generation sequencing using unique molecular identifiers (2021) (4)
- Comment to: The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 2007; 92:1335-1342 (2008) (4)
- Alternating Chemotherapy Does Not Improve Results in Poor-prognosis Aggressive Lymphomas - Lnh87 Protocol Group-3 - a Gela Study (1993) (4)
- Comparison Between 2 D and 3 D Dosimetry Protocols in 90 Y-Ibritumomab Tiuxetan Radioimmunotherapy of Patients with Non-Hodgkin ’ s Lymphoma (2008) (4)
- [Preventive treatment of infection caused by gram-negative bacteria using anti-lipopolysaccharide antibodies. Evaluation in patients with aplasia]. (1989) (4)
- diagnosed acute promyelocytic leukemia: a pilot study on 26 cases complete remission rate and may prolong remissions in newly All-transretinoic acid followed by intensive chemotherapy gives a high (2011) (4)
- Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study (2015) (4)
- Prognostic value of PET-CT after frontline therapy in follicular lymphoma: A pooled analysis of central review in three multicenter studies. (2014) (3)
- Outcome of Relapsed AML Patients Aged between 50 and 70: The ALFA Group Experience (ALFA 9801 Study). (2007) (3)
- Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial (2019) (3)
- Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial (2021) (3)
- A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX). (2018) (3)
- Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL). (2019) (3)
- [Primary pleural lymphoma after collapse therapy: modern aspects of an historic disease]. (1999) (3)
- Transient anti rhesus alloantibody produced by graft after non-myeloablative allogeneic stem cell transplant. (2004) (3)
- Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials (2017) (3)
- Phase I Study of Escalating Doses of Lenalidomide Combined with R-CHOP (R2-CHOP) for Front-Line Treatment of B-Cell Lymphomas (2011) (3)
- Application of the cghRA framework to the genomic characterization of Diffuse Large B‐Cell Lymphoma (2017) (3)
- Allogeneic Stem Cell Transplantation (allo-SCT) for Isolated and Leukemic Myeloid Sarcoma (GS): a Survey on Behalf of the Acute Leukemia Working Party (ALWP) of EBMT. (2010) (3)
- Brain Perfusion in Adult Patients with Acute Myeloblastic Leukemia before and after Cytosine Arabinoside (2011) (3)
- Targeted EZH2 Inhibitors in Diffuse Large B-Cell Lymphoma (DLBCL): Immunohistochemical and Mutational Profiles of Patients May Determine Candidates for Treatment (2014) (3)
- [Spontaneous remission of refractory anemia with excess of blasts after septicemia]. (1987) (3)
- Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma ( LNH 03-1 B ) (2013) (3)
- prospective Phase Ii Trial Of Lenalidomide In Association With Chop In Elderly Patients With Angioimmunoblastic T Cell Lymphoma (aitl): Interim Analysis Of A Lysa Study : 101 (2015) (3)
- Response to A+CHP by CD30 expression in the ECHELON-2 trial. (2019) (3)
- Impact of the intensity of conditioning regimen in 144 patients with follicular lymphoma (FL) receiving a matched unrelated donor stem cell transplant (MUD-SCT): An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (LWP-EBMT) (2008) (3)
- Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance (2021) (3)
- [Treatment of malignant hemopathies with aracytine in low doses. Analysis of 159 cases]. (1985) (3)
- R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa Centers (2020) (3)
- Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study (2022) (3)
- S1600 REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM (2019) (3)
- [Chronic hepatitis as complication of cirrhosis, due to papaverine]. (1981) (3)
- Angiogenesis imaging study using interim [18F] RGD-K5 PET/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence (2021) (3)
- Zanolimumab, a fully human monoclonal antibody: preliminary results of an ongoing clinical trial in CD4+ peripheral T-cell lymphomas (PTCL) (2006) (3)
- SUVmax-based assessment of PET response shows a superior specificity to Deauville criteria for predicting recurrence in Hodgkin’s lymphoma (2020) (3)
- P115 Prognostic factors in chronic myelomonocytic leukaemia: a retrospective analysis of 113 patients (2007) (3)
- Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor- risk BDLC NHL patients treated with up-front consolidative autotransplantation: A GELA phase II trial (LNH 2003-3). (2009) (3)
- [Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment]. (2017) (3)
- Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor Burden Follicular Lymphoma. A Pooled Analysis of Three Multicenter Studies (2015) (2)
- Ibrutinib in Association with R-DHAP/Ox for Patients with Relapsed/Refractory B-Cell Lymphoma: Preliminary Results of the Biblos Phase Ib Lysa Study (2016) (2)
- Significant Prognostic Impact of [18F]Fluorodeoxyglucose-PET Scan Performed During and At the End of Treatment with R-CHOP in High-Tumor Mass Follicular Lymphoma Patients: A GELA-GOELAMS Study (2011) (2)
- Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma (2016) (2)
- Gene Expression Profile Associated with Survival in Patients with Diffuse Large B-Cell Lymphoma Treated by Chemotherapy and Rituximab. (2005) (2)
- Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group. (2021) (2)
- A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study (2013) (2)
- A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untretated Follicular B-Cell Lymphoma in Need of Systemic Therapy (2018) (2)
- Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The French Lymphoma Study Association (LYSA) Registry Data (2018) (2)
- Prognostic value of response after three MOPP cycles in hodgkin's disease — stage III and IV (1987) (2)
- Hypoalbuminemia and hypergammaglobulinemia are associated with an increased infection risk in patients with myeloid malignancies treated with azacitidine. A 3-year monocentric retrospective study (2016) (2)
- Systemic ALK-Positive Anaplastic Large-Cell Lymphoma (ALCL): Final Analysis of an International, Individual Patient Data Study of 263 Adults (2017) (2)
- Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low–intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol (2010) (2)
- A New Immunohistochemical Algorithm Using Four Antibodies Has a High Concordance with Gene Expression Profiling Defined ABC and GCB Diffuse Large B-Cell Lymphoma (2017) (2)
- Rituximab maintenance after autologous stem‐cell transplantation in patients with mantle cell lymphoma, final result of the LyMA trial conducted on behalf the LYSA group (2017) (2)
- Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (2)
- Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Results of the Selinda Phase Ib Lysa Study (2021) (2)
- Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area. (2017) (2)
- Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response (2020) (2)
- CNS relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL. (2021) (2)
- Hematological reconstitution after autologous peripheral blood transplantation. (1987) (2)
- Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients (2016) (2)
- Rituximab maintenance after combined immuno-chemotherapy significantly prolongs duration of remission in elderly patients with mantle cell lymphoma (2011) (2)
- PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND EZH2 MUTATION, IN NHL PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR DNA (2017) (2)
- Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study (2018) (2)
- Phase II Study of Enzastaurin in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma. (2006) (2)
- Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study. (2016) (2)
- Reply to H.J.A. Adams et al and E. Laffon et al. (2017) (2)
- Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study (2020) (2)
- [Role of double induction in the treatment of acute myeloblastic leukemia in the adult: intermediate results of protocol LAM90]. (1994) (2)
- Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes (2022) (2)
- Haploidentical Transplantation Using High Dose Post-Transplant Cyclophosphamide for Patients with Aplastic Anemia : The European Group for Blood and Marrow Transplantation Experience (2018) (2)
- Late intensification is superior to early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma. A randomized study from the GELA: LNH RP93. (1997) (2)
- Recurrent disruption of the Imu splice donor site in t(14;18) positive lymphomas: a potential molecular basis for aberrant downstream class switch recombination. (2007) (2)
- Ibrutinib in association with R-DHAP/ox for patients with relapsed/refractory b-cell lymphoma: Results of the escalating phase of the BIBLOS phase Ib LYSA study. (2018) (2)
- Development of a multiplex PCR assay for the detection of genomic copy number changes in myelodysplastic syndromes. (2009) (2)
- Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT (2022) (2)
- [Production of hyaluronan-binding glycoprotein by human monocytes. Its use as marker in myeloid leukemia]. (1992) (2)
- Autologous stem cell transplantation (ASCT) for elderly patients (>= 60 years) with non-hodgkin's lymphoma (NHL): An analysis based on EBMT registry. (2007) (2)
- The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World (2020) (2)
- Severe Acquired Neutropenia Associated with Anti-Proteinase 3 Antibodies (2011) (2)
- Gene Expression Profiling of Highly Purified Malignant and Non-Malignant Cells: Characterization of the Tumor-Microenvironment Cellular Synapse in De Novo Follicular Lymphoma (FL). (2007) (2)
- Double Hit Lymphoma Diagnosis and Treatment in Europe—A Cross-Sectional Survey of Clinical Practice by the EHA Lymphoma Working Party (EHA LyG) (2020) (2)
- Phase 1b Study Of Everolimus (RAD001), a mTORC1 Inhibitor In Combination With Rituximab (R), In Patients With Relapsed Or Refractory Indolent CD20+ Lymphomas Or Transformed Aggressive CD20+ Lymphomas (2013) (1)
- ALL Transretinoic Acid Followed by Intensive Chemotherapy in Newly Diagnosed Acute Promyelocytic Leukemia: A Pilot Study on 27 Cases (1994) (1)
- Genetic Reconstruction of Follicular Lymphoma Evolutions: Sμ Mutations Studies Suggest Two Progression Patterns, Early Direct or Late from FL “Stem Cells”. (2007) (1)
- Outcomes after intensive care unit admission in newly diagnosed diffuse large B‐cell lymphoma patients: A real‐life study (2021) (1)
- Comparison of a Quantitative PCR Method with FISH for the Assessment of the Four Aneuploïdies Commonly Evaluated in CLL Patients. (2006) (1)
- Integrated Analysis of IGHV Gene Status, Cell-of-Origin Signature and Genomic Features in Diffuse Large B-Cell Lymphoma (2016) (1)
- Final Results of a Phase I Study of the Anti-CD79b Antibody-Drug Conjugate DCDS4501A (Polatuzumab Vedotin) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 4400 (2013) (1)
- Multiple cutaneous ulcers revealing a primary cutaneous Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma (2020) (1)
- Three chop followed by radiotherapy versus a more intensive chemotherapy alone in low risk localized aggressive non Hodgkin’s lymphoma (NHL): Preliminary results of the Gela-LNH 93-1 study (2001) (1)
- [Recurrent pleural pericarditis]. (1996) (1)
- [Prognostic factors of malignant non-Hodgkin's lymphoma]. (1996) (1)
- Economic burden in non‐Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross‐sectional study (2021) (1)
- SPLENECTOMY BEFORE BONE MARROW TRANSPLANTATION IN CHRONIC GRANULOCYTIC LEUKAEMIA (1986) (1)
- [Treatment options in non-Hodgkin lymphomas]. (2010) (1)
- Autologous blood stem cell collection after chemotherapy for malignancies : data for an optimal yield (1990) (1)
- Ocular adnexal marginal zone B-cell lymphoma: the low-dose dilemma (2019) (1)
- Final Analysis of the International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL in Response after R-CHOP, the Remarc Study from Lysa (2020) (1)
- Rituximab plus gemcitabine and oxaliplatine (R-GemOx) in refractory/relapsed patients with diffuse large B-cell lymphoma (DLBCL) who are not candidates for high-dose therapy (HDT): A GELA study. (2010) (1)
- Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA. (2021) (1)
- A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2019) (1)
- Rituximab Combined to ACVBP (R-ACVBP) Supported by Pegfilgrastim as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Results of LNH 03–39B. A GELA Study. (2007) (1)
- The EHA Research Roadmap: Malignant Lymphoid Diseases (2022) (1)
- The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working Party (2011) (1)
- Phylogenetic Evolution in Refractory/Relapsed Diffuse Large B-Cell Lymphoma (2012) (1)
- standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma Intensive conventional chemotherapy (ACVBP regimen) compared with (2009) (1)
- Iron Parameters and Relation To Prognosis In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study (2013) (1)
- Single nucleotide polymorphisms in ABCB 1 and CBR 1 can predict toxicity to R-CHOP type regimens in patients with diffuse non Hodgkin lymphoma by (2015) (1)
- PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38) (2021) (1)
- Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the Phase 3 POLARIX trial. (2023) (1)
- [Differential diagnosis of lymphomas]. (2002) (1)
- Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). (2022) (1)
- RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN (R‐GemOx) IN REFRACTORY/RELAPSED (R/R) DLBCL. A REAL LIFE STUDY IN PATIENTS INELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION (2019) (1)
- Inhibition of Hedgehog Signaling for the Treatment of Lymphoma and CLL: A Phase II Study from the Lysa (2015) (1)
- Promoter Shuffling by Sequential Genomic Rearrangements in Follicular Lymphoma Reveals an Ongoing Genomic Instability at the BCL6 Locus. (2006) (1)
- Miescher cheilitis and myelomonocytic leukemia: a fortuitous association or a rare paraneoplastic syndrome? (2010) (1)
- A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis (2022) (1)
- Assessing the Cox model assumption as a statistical tool for classifying lymphomas. (2001) (1)
- Sinusoidal Obstruction Syndrom (SOS): Warning about Autologous Stem Cell Transplantation (ASCT) Preceded By Regimens Containing Oxaliplatin (2018) (1)
- Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial (2022) (1)
- Concomitant occurrence of genetically distinct Hodgkin lymphoma and primary mediastinal lymphoma (2021) (1)
- CNS prophylaxis in diffuse large B-cell lymphoma – Authors' reply (2012) (1)
- Combined Genotype Analysis of Tumor and Cell-Free DNA By Ultra-Deep Targeted Sequencing: Correlation with PET-Scan Imaging in a Prospective Cohort of Diffuse Large B-Cell Lymphoma Patients (2017) (1)
- Gene Expression Profile Analysis According to Recurrent Gene Copy Number Abnormalities Defines a Diffuse Large B-Cell Lymphoma Subgroup Characterized by 9p21 Locus Deletion, Ribosome Machinery Deregulation and Poor Prognosis. A GELA Study (2008) (1)
- Combining Gene Expression Profiling and Artificial Intelligence to Diagnose B-Cell Non-Hodgkin Lymphoma (2019) (1)
- Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma (2022) (1)
- BONE MARROW INVOLVEMENT, BUT NO BLOOD INVOLVEMENT, IMPAIRS SURVIVAL IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: AN ANCILLARY STUDY OF THE REVAIL TRIAL (2019) (1)
- Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study (2015) (1)
- Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient (2018) (1)
- Bendamustine Treatment in Refractory or Relapsed T Cell Lymphomas: A Retrospective Multicenter Study (2015) (0)
- Updated Results Confirm Favorable Outcome of Immunocompetent Patients with Primary CNS Lymphoma Treated By C5R Protocol in Combination with Intravenous Rituximab and Intrathecal Liposomal Cytarabine: A Multicentric Prospective Phase 2 Study of the Lymphoma Study Association (LYSA) (2014) (0)
- Long-term excess mortality and net survival among elderly diffuse large B-cell lymphoma patients after front-line R-CHOP treatment. (2023) (0)
- Prognostic relevance of lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience (2021) (0)
- Single Nucleotide Polymorphisms in ABCB1 and CBR1 Predict Toxicity to R-CHOP Type Regimens in Patients with Diffuse Non Hodgkin's Lymphoma (2012) (0)
- non-Hodgkin's lymphoma (see comments) Translocations involving band 3q27 and Ig gene regions in (2011) (0)
- PVRL2 is translocated to the TCRA locus in t(14;19)(q11;13) positive peripheral T-cell lymphoma (2006) (0)
- A Quantitative Multiplex PCR Assay, Validated by a High Resolution Array Comparative Genomic Hybridization Analysis, Provides Information Regarding Genomic Imbalances and Prognosis in Diffuse Large B-Cell Lymphomas. (2006) (0)
- Distinct Expression Patterns of microRNAs in Activated B Cell (ABC) and Germinal Center B (GC) Subtypes of Diffuse Large B Cell Lymphoma (DLBLC). (2007) (0)
- THE CLINICAL COURSE OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) OVER TIME: A MULTISTATE SURVIVAL ANALYSIS USING META‐DATA FROM 13 FIRST‐LINE RANDOMIZED TRIALS (2019) (0)
- Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The Lymphoma Study Association (LYSA) Registry Data (2019) (0)
- Novel markers for determining risk and evaluation of minimal residual disease in diffuse large B-cell lymphoma (2018) (0)
- Improving high-resolution copy number variation analysis from next generation sequencing using unique molecular identifiers (2021) (0)
- REFINEMENT OF MUM1 EXPRESSION THRESHOLD FOR DOUBLE POSITIVE CD10+ MUM1+ DIFFUSE LARGE B CELL LYMPHOMA ALLOWS A BETTER CELL OF ORIGIN CLASSIFICATION FOR GCB SUBTYPE (2019) (0)
- Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study) (2019) (0)
- Clinical Relevance Of Cachexia Assessed By An Anthropometric Tool In Elderly Patients With Diffuse Large B-Cell Lymphoma Treated By Immunochemotherapy (2013) (0)
- HIGH ADIPOSE TISSUE DENSITY IS A NEGATIVE PROGNOSTIC FACTOR IN DLBCL PATIENTS TREATED BY R‐CHOP, INDEPENDENT FROM TMTV AND PS –FROM THE REMARC STUDY (2021) (0)
- Hepatosplenic γδ T-cell Lymphoma is a Rare Clinicopathologic Entity with Poor Outcome : Report on a Series of 21 Cases . Short title : HEPATOSPLENIC γδ T-CELL LYMPHOMA (2003) (0)
- Non Germinal-Center B Cell Like Diffuse Large B Cell Lymphoma Results From Repeated Activation of IgM B Cells That Resist Class-Switching. (2009) (0)
- [Treatment of aggressive primary lymphomas of the digestive system by intensive chemotherapy. Experience of the Study Group on Lymphomas in Adults with the LNH-84 protocol]. (1992) (0)
- Authors' Reply. (2018) (0)
- Radiologists are influenced by the PET when analyzing the CT during follow-up of patients with lymphoma (2007) (0)
- Poster: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the P (2022) (0)
- Patient-Specific Three Dimensional (3D) Dosimetry for 90Y Ibritumomab Tiutexan (Zevalin®) in Patients with Follicular Lymphoma. (2005) (0)
- Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose Therapy with Stem-Cell Transplantation in Poor Risk Patients with Diffuse Large B-Cell Lymphoma (2012) (0)
- Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK‐cell counts in rituximab–chemotherapy responsive elderly DLBCL patients: A LYSA group study (2023) (0)
- THE 5‐YEAR FOLLOW‐UP RESULTS OF THE C5R PROTOCOL WITH RITUXIMAB AND INTRATHECAL LIPOSOMAL CYTARABINE FOR PRIMARY CNS LYMPHOMA: A PROSPECTIVE PHASE 2 STUDY OF THE LYSA (2017) (0)
- [Systemic lupus erythematosus and hereditary deficiency of complement C2]. (1979) (0)
- Serum 2-Hydroxyglutarate in Angioimmunoblastic T Cell Lymphomas: A New Marker for IDH2 Mutation Detection and Monitoring (2018) (0)
- ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III (2022) (0)
- Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma (2022) (0)
- Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial (2020) (0)
- Comparison Between Short Course (Single Fraction) and Long Course (Multiple Fractions) on Pain Relief in Patients With Bone Localization of Multiple Myeloma (2014) (0)
- Major dispersion in etoposide systemic exposure in malignant lymphoma patients receiving BEAM high dose chemotherapy followed by ABMT: A multicentre study of the Groupe d’Etudes des Lymphomes de l’Adulte (GELA) (2008) (0)
- COMPARISON OF CLINICAL SCORING SYSTEMS IN AGGRESSIVE B‐CELL LYMPHOMAS (BCL): AN INDIVIDUAL PATIENT‐LEVEL ANALYSIS ACROSS INTERNATIONAL TRIAL (2019) (0)
- Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study (2022) (0)
- A Molecular Classifier Increased the Accuracy of Lymphoma Diagnosis By Expert Pathologists in the Diffuse Large B-Cell Lymphoma Gained Trial from the Lysa (2021) (0)
- Bone-marrow Transplantation Prolongs Survival After Relapse in Lymphoma Patients - Long-term Follow-up (1993) (0)
- Genomic Regions Supporting microRNA Expression and Their Biogenesis Are Globally Conserved in Diffuse Large B-Cell Lymphomas (DLBCL) and Display a Limited Number of Homozygous Deletions or Amplifications. (2007) (0)
- REMARC STUDY: CORRELATION OF LYMPHOMA PD AND DEATH AND HEALTH‐RELATED QOL WITH MAINTENANCE LENALIDOMIDE VS PLACEBO IN ELDERLY DLBCL PATIENT RESPONDERS TO R‐CHOP (2017) (0)
- Autologous Stem Cell Transplantation (ASCT) for Patients Aged 60 Years or Older with Classical Hodgkin Lymphoma : A Retrospective Analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC) (2014) (0)
- P-077 Cytogenetic contribution in the diagnosis of chronic cytopenias without dysplasia (2013) (0)
- The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study (2022) (0)
- Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study. (2023) (0)
- Subcutaneous rituximab induction followed by short rituximab maintenance to improve progression-free survival in patients with low-tumor burden follicular lymphoma: Final results of FLIRT phase III trial, a LYSA study. (2022) (0)
- Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group (2022) (0)
- 125 FEBRILE EPISODES IN PATIENTS WITH MDS TREATED WITH AZACITIDINE. A THREE YEAR MONOCENTRIC RETROSPECTIVE STUDY (2015) (0)
- Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial (2022) (0)
- study from the GELA patients with advanced follicular lymphoma: the GELF-94 randomized high-dose therapy with autologous stem cell transplantation in untreated Standard chemotherapy with interferon compared to CHOP followed by (2013) (0)
- Development of a Multiplex PCR Assay for the Detection of Genomic Copy Number Changes in Myelodysplastic Syndromes (2008) (0)
- INTEGRATIVE ANALYSIS OF FEATURES ASSOCIATED WITH TET2, IDH2, DNMT3A, AND RHOA MUTATIONS IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: A LYSA STUDY (2017) (0)
- Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/ DSHNHL analysis. (2023) (0)
- Persistance of loss of the Y chromosome during long-lasting complete remission in a case of acute myelogenous leukemia treated with low-dose cytosine arabinoside (1986) (0)
- Abstract 4810: Exome sequencing of refractory diffuse large B-cell lymphomas highlights candidate genes for targeted resequencing (2015) (0)
- Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study (2022) (0)
- Prognostic Role of Host Immune Gene Polymorphisms for Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab and Chemotherapy. A Study Based on 554 Patients Included in the GELA (Groupe d'Etude des Lymphomes de l'Adulte) Prospective Multicentric Program LNH2003, (2011) (0)
- A Dedicated Program for Young Adults who Suffer from Cancer: Experience of the Centre Henri Becquerel, Rouen, France (2014) (0)
- Chemotherapy-free treatment in unfit patients aged 75 years and older with DLBCL: toward a new paradigm? (2022) (0)
- PET/CT Before Autologous Stem Cell Transplantation Predicts Outcome In High-Risk, Relapsed Follicular Lymphoma (2013) (0)
- INVOLVES THE BONE MARROW (BM) AND LIVER WITH INTRASINUSOIDAL LYMPHOMATOUS INFILTRATION (ISLI). A PROPOSAL FOR THE BLOOD DEFENSE SYSTEM (BDS) AND RELATED LYMPHOMAS (2008) (0)
- Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study (2014) (0)
- GENE EXPRESSION PROFILING USING a RTMLPA ASSAY ALLOWS FOR AN ACCURATE CLASSIFICATION OF PERIPHERAL T‐CELL LYMPHOMA AND HIGHLIGHTS NOVEL SUBGROUPS WITHIN PTCLS‐NOS (2017) (0)
- Invasive Geotrichum clavatum Fungal Infection in an Acute Myeloid Leukaemia Patient: A Case Report and Review (2014) (0)
- Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma (2020) (0)
- CHARACTERISTICS OF PATIENTS ACHIEVING COMPLETE OR PARTIAL RESPONSE (CR/PR) WITH TAZEMETOSTAT (TAZ) IN WILD‐TYPE RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) (2021) (0)
- Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first‐line treatment for patients with diffuse large B‐cell lymphoma (2022) (0)
- Sinusoidal Obstruction Syndrome: Warning About Autologous Stem Cell Transplantation Preceded by Regimens Containing Oxaliplatin (2019) (0)
- Abstract 4921: Population pharmacokinetic modeling of ibrutinib administered in patients with relapsed or refractory B cell malignancies eligible for autologous stem cell transplantation (2018) (0)
- A Very Short Mutational Hot-Spot in the IGH 5′Sμ Region Suggests That the Acquisition of a Class Switch Recombination Defect Is an Important Step Toward Lymphomagenesis. (2005) (0)
- Abstract 4947: HACE1 is a putative tumor suppressor gene in B-cell lymphomagenesis down-regulated by both deletion and epigenetic mechanisms (2015) (0)
- A multicenter study of 66 patients with spinal cord compression at diagnosis of B-cell non-Hodgkin lymphoma. (2014) (0)
- Interim 18F-Fluorodeoxyglucose PET scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab (2012) (0)
- Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy (2022) (0)
- Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study (2018) (0)
- Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system. (2016) (0)
- Prognostic Value Of Red Blood Cell and Platelet Transfusion In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study (2013) (0)
- A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma (2022) (0)
- [Surveillance of patients treated for lymphoma]. (1993) (0)
- Shortened Firs t-Line High-Dose Chemotherapy for Pat ients With Poor-Prognosis Aggress ive Lymphoma (2002) (0)
- Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study (2022) (0)
- Cytokine Gene Polymorphisms and Outcome of Patients with Hodgkin Lymphoma: A Prospective Study of the Groupe D’Etude Des Lymphomes De L’Adulte (2008) (0)
- 121 Myelodysplastic syndrome and 17P deletion (1997) (0)
- Impact of Reduced Dose Intensity for Elderly Patients with Diffuse Large B-CELL Lymphoma Receiving R-CHOP Every 14 or 21 Days: An Analysis of the LNH03–6B GELA Study. (2012) (0)
- Incidence and Clinicopathological Relevance of Gene Copy Number Abnormalities Detected by a Single Quantitative PCR Assay in Mantle Cell Lymphomas. (2008) (0)
- P. glycoprotein (PGP) expression and response to intensive chemotherapy and low dose AraC in myelodysplastic syndromes (MDS). A report on 66 cases (1994) (0)
- IPI24 supplemental material submitted (2015) (0)
- Angiogenesis Imaging Study Using [18F] RGD-K5 PET/CT in Patients with Lymphoma Under Chemotherapy. (2020) (0)
- RT-MiS : Un Nouvel Outil Diagnostique Pan-Lymphomes (2019) (0)
- Sarcopenia Determined by Computed Tomography Imaging Is an Independant Prognostic Factor in Elderly Patients with Diffuse Large B CELL Lymphoma Treated by Immunochemotherapy (2012) (0)
- Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final Results of 18 Patients Treated at RP2D of Selinexor in the Selinda Phase Ib Lysa Study (2022) (0)
- 5' Rapid amplification of cDNA ends (5'RACE): A simpler method to analyze immunoglobulin genes and discover the value of the light chain in chronic lymphocytic leukemia. (2022) (0)
- Comparison of bone marrow trephine sample quality between a drill-powered system and a manual needle system. (2022) (0)
- Prognostic value of etoposide area under the curve (AUC) in lymphoma patients treated with BEAM regimen and ASCT: Multicenter study of Groupe d’Etudes des Lymphomes de l’Adulte (GELA). (2012) (0)
- Le purpura thrombotique thrombocytopénique ou syndrome de Moschcowitz. Quoi de nouveau (1986) (0)
- 1639P Integrated safety analysis of tazemetostat (TAZ) 800 mg BID in adult patients (pts) with hematologic and solid tumors (2020) (0)
- P096 AML/MDS with chromosome 5 and 7 abnormalities (2007) (0)
- Histological Characteristics Of Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. Results Of The French Lympho-C ANRS HC-13 Multicentric Study Of 133 Patients (2013) (0)
- Paper 81946 abstract 160359 0 (2015) (0)
- Response to the EZH2 Inhibitor Tazemetostat Is Independent of Cell of Origin Determined Via Hans Imunohistochemistry or Nanostring Lymphoma Subtyping Test in EZH2 Wild-Type DLBCL Patients (2017) (0)
- Highly Multiplexed Targeted Sequencing of Recurrent Fusion Genes in Acute Leukemia (2014) (0)
- Analysis of peripheral neuropathy (PN) using clinician- and patient-reported outcomes (ClinRO and PRO) in the POLARIX study. (2022) (0)
- EZH2-Activating Mutations in DLBCL Are Easily Predictable by Routine Immunohistochemistry Analysis: a Tool to More Efficiently Define EZH2 Inhibitor-Sensitive Patients? (2015) (0)
- ALFA-9000 Trial - An Analysis of Cytogenetic Subsets: Significant Long-Term Benefit of Early Induction Reinforcement Is Observed in CBF-AML Only. (2005) (0)
- Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy (2021) (0)
- Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx (2020) (0)
- Diffuse large B-cell lymphoma refractory to R-CHOP SUMMARY (2018) (0)
- DEFINING ULTRA‐HIGH‐RISK DLBCL PATIENTS PRIOR TO INITIAL TREATMENT BASED ON AN INTEGRATIVE HOST AND DISEASE PROGNOSTIC SCORE (FROM REMARC STUDY) (2021) (0)
- The 5q-syndrome: Clinical course of 12 patients (1994) (0)
- Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa Studies (2016) (0)
- Complete Response After High-Dose Methotrexate-Based Chemotherapy as a Major Prognostic Factor for Primary CNS Lymphoma: An Exploratory Analysis of the LNHCP93 Trial of the Groupe d'Etude Des Lymphomes De l'Adulte (2009) (0)
- Intensive Therapy of Myelodysplastic Syndromes and Secondary Leukemias: Preliminary Findings of the French Experience (1997) (0)
- Mutations of STAT6 DNA Binding Domain Are Characteristic of PMBL and Belong to the Genetic Signature of This Entity. (2012) (0)
- RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY (2019) (0)
- [Must low-burden aggressive lymphomas be treated with intensive chemotherapy? (LNH-87, Group 1)]. (1993) (0)
- Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study (2020) (0)
- Contents Vol. 126, 2011 (2011) (0)
- Sub-Cutaneous Administration of Rituximab Triggers a Pro-Phagocytic Phenotype of Monocytic Compartment in Low-Tumor Burden Follicular Lymphoma Patients Included in the Flirt Clinical Trial, a Lysa Study (2022) (0)
- Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper (2022) (0)
- Molecular genetics of diffuse lymphoma: the LAZ3/BCL6 gene (1996) (0)
- Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation (2019) (0)
- Oral Abstract: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results Fro (2022) (0)
- [Clinical application of gene-expression profiling in lymphome]. (2004) (0)
- Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort (2018) (0)
- 282 Familial myelodysplastic syndrome/acute myeloid leukemia (MDS/AML): Report of 2 families (2011) (0)
- Histology of Lymphomas with t(3;14)(q27;q32) Correlates with the Molecular Anatomy of the Translocation. (2005) (0)
- The germinal Center B-cell signature is associated to a higher [18F]-FDG uptake and improves the prognosis value of TEP scan in diffuse large B-celle lymphomas (DLBCL) treated by rituximab(R) and anthracyclines-based chemotherapy. (2010) (0)
- Estimating the impact of rituximab on bcl-2-associated resistance to CHOP using competing risks in elderly patients with diffuse large B-cell lymphoma (DLBCL). (2006) (0)
- 323 Prognostic impact of cytogenetics in a series of 560 patients with myelodysplastic syndrome in a single institution (2011) (0)
- Ancestim (stem cell factor, SCF) in combination with filgrastim can mobilize sufficient peripheral blood progenitor cells (PBPC) to support high-dose salvage chemotherapy and late intensification in relapsing and refractory aggressive non-Hodgkin's lymphoma. A GELA study. (2003) (0)
- Prognostic Value of Lymphocyte-Monocyte Ratio in Primary Myelodysplastic Syndrome (2017) (0)
- Quality of life in 269 poor-risk diffuse large B-cell lymphoma patients treated with rituximab versus observation after front-line auto transplantation: The GELA LNH98-3 randomized trial. (2010) (0)
- De Novo t(14;18) Diffuse Large B-Cell Lymphoma Is Characterized by a Germinal Center B Cell-Like Phenotype and Acquisition of Glycosylation Sites by Somatic Mutation in Immunoglobulin VH Genes. (2004) (0)
- [Treatment of acute leukemia]. (1985) (0)
- Impact of Cytogenetics on Outcome after Allogeneic Transplantation for Myelodysplastic Syndrome or Post MDS Secundary Myeloid Leukemia (2017) (0)
- Sarcopenia Determined by Computed Tomography (CT) imaging is a Better Prognosis Factor Than Albuminemia or Charlson Index in Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL), (2011) (0)
- Gene Expression Profiling Using a Reverse Transcriptase-Multiplex Ligation Dependant Probe Amplification Assay Allows for an Accurate Classification of Peripheral T-Cell Lymphoma and Highlights Novel Subgroups within the PTCL-NOS Category (2016) (0)
- Invasive Aspergillosis in Neutropenic Patients During Hospital Renovation: Effectiveness of Mechanical Preventive Measures in a Prospective Cohort of 438 Patients (2015) (0)
- Anaplastic large cell lymphoma in adults (2010) (0)
- High Prevalence of Pre-Existing Sarcopenia in Critically Ill Patients with Hematologic Malignancies Admitted to the Intensive Care Unit for Sepsis or Septic Shock (2023) (0)
- Impact of Rituximab on Peripheral Blood Stem Cell Mobilization and Collection Following ACVBP Regimen in Poor Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Large Cohort of Patients from Two Prospective GELA Trials. (2008) (0)
- Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone: until what age? (2012) (0)
- SAFETY AND EFFICACY OF ATEZOLIZUMAB, OBINUTUZUMAB AND VENETOCLAX COMBINATION FOR RELAPSED/REFRACTORY NON‐HODGKIN LYMPHOMAS: RESULTS FROM THE SAFETY‐RUN OF A LYSA STUDY (2019) (0)
- Autologous stem cell transplantation (ASCT) for elderly patients (>= 60 years) with non-hodgkin's lymphoma (NHL) (2007) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Hervé Tilly?
Hervé Tilly is affiliated with the following schools:
